Literature DB >> 16154712

Intensity-modulated radiation therapy for the treatment of nonanaplastic thyroid cancer.

Benjamin D Rosenbluth1, Victoria Serrano, Laura Happersett, Ashok R Shaha, R Michael Tuttle, Ashwatha Narayana, Suzanne L Wolden, Kenneth E Rosenzweig, Lanceford M Chong, Nancy Y Lee.   

Abstract

PURPOSE: Intensity-modulated radiation therapy (IMRT) enables highly conformal treatment for thyroid cancer (TC). In this study, we review outcomes/toxicity in a series of TC patients treated with IMRT. METHODS AND MATERIALS: Between July 2001 and January 2004, 20 nonanaplastic TC patients underwent IMRT. Mean age was 55. There were 3 T2 and 17 T4 patients. Sixteen patients had N1 disease. Seven patients had metastases before RT. Fifteen underwent surgery before RT. Radioactive iodine (RAI) and chemotherapy were used in 70% and 40%, respectively. Median total RT dose was 63 Gy.
RESULTS: With two local failures, 2-year local progression-free rate was 85%. There were six deaths, with a 2-year overall survival rate of 60%. For patients with M0 disease, the 2-year distant metastases-free rate was 46%. The worst acute mucositis and pharyngitis was Grade 3 (n = 7 and 3, respectively). Two patients had Grade 3 acute skin toxicity and 2 had Grade 3 acute laryngeal toxicity. No significant radiation-related late effects were reported.
CONCLUSIONS: IMRT for TC is feasible and effective in appropriately selected cases. Acute toxicity is manageable with proactive clinical care. Ideal planning target volume doses have yet to be determined. Additional patients and long-term follow-up are needed to confirm these preliminary findings and to clarify late toxicities.

Entities:  

Mesh:

Year:  2005        PMID: 16154712     DOI: 10.1016/j.ijrobp.2005.05.043

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  25 in total

Review 1.  A systematic review of dysgeusia induced by cancer therapies.

Authors:  Allan J Hovan; P Michele Williams; Peter Stevenson-Moore; Yula B Wahlin; Kirsten E O Ohrn; Linda S Elting; Fred K L Spijkervet; Michael T Brennan
Journal:  Support Care Cancer       Date:  2010-05-22       Impact factor: 3.603

2.  Adjuvant external beam radiation for medullary thyroid carcinoma.

Authors:  Steve R Martinez; Shannon H Beal; Allen Chen; Steven L Chen; Philip D Schneider
Journal:  J Surg Oncol       Date:  2010-08-01       Impact factor: 3.454

Review 3.  A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: management strategies and economic impact.

Authors:  S B Jensen; A M L Pedersen; A Vissink; E Andersen; C G Brown; A N Davies; J Dutilh; J S Fulton; L Jankovic; N N F Lopes; A L S Mello; L V Muniz; C A Murdoch-Kinch; R G Nair; J J Napeñas; A Nogueira-Rodrigues; D Saunders; B Stirling; I von Bültzingslöwen; D S Weikel; L S Elting; F K L Spijkervet; M T Brennan
Journal:  Support Care Cancer       Date:  2010-03-25       Impact factor: 3.603

Review 4.  An evidence-based review of poorly differentiated thyroid cancer.

Authors:  Enoch M Sanders; Virginia A LiVolsi; James Brierley; Jennifer Shin; Gregory W Randolph
Journal:  World J Surg       Date:  2007-05       Impact factor: 3.352

5.  IMRT and IGRT in head and neck cancer: Have we delivered what we promised?

Authors:  Gupta Tejpal; Agarwal Jaiprakash; Bannerjee Susovan; Sarbani Ghosh-Laskar; Vedang Murthy; Ashwini Budrukkar
Journal:  Indian J Surg Oncol       Date:  2010-11-21

6.  Intensity-modulated radiation therapy use for the localized treatment of thyroid cancer: Nationwide practice patterns and outcomes.

Authors:  Paolo Goffredo; Timothy J Robinson; Linda M Youngwirth; Sanziana A Roman; Julie A Sosa
Journal:  Endocrine       Date:  2016-03-30       Impact factor: 3.633

7.  External-beam radiotherapy for differentiated thyroid cancer locoregional control: A statement of the American Head and Neck Society.

Authors:  Ana P Kiess; Nishant Agrawal; James D Brierley; Umamaheswar Duvvuri; Robert L Ferris; Eric Genden; Richard J Wong; R Michael Tuttle; Nancy Y Lee; Gregory W Randolph
Journal:  Head Neck       Date:  2015-12-30       Impact factor: 3.147

8.  Guidelines for radioiodine therapy of differentiated thyroid cancer.

Authors:  M Luster; S E Clarke; M Dietlein; M Lassmann; P Lind; W J G Oyen; J Tennvall; E Bombardieri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-10       Impact factor: 9.236

9.  Intensity modulated radiotherapy with concurrent chemotherapy for larynx preservation of advanced resectable hypopharyngeal cancer.

Authors:  Wen-Yen Huang; Yee-Min Jen; Chang-Ming Chen; Yu-Fu Su; Chun-Shu Lin; Yaoh-Shiang Lin; Ying-Nan Chang; Hsing-Lung Chao; Kuen-Tze Lin; Li-Ping Chang
Journal:  Radiat Oncol       Date:  2010-05-15       Impact factor: 3.481

10.  Postoperative external beam radiotherapy for differentiated thyroid cancer: outcomes and morbidity with conformal treatment.

Authors:  David L Schwartz; Mark J Lobo; K Kian Ang; William H Morrison; David I Rosenthal; Anesa Ahamad; Douglas B Evans; Gary Clayman; Steven I Sherman; Adam S Garden
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-12-25       Impact factor: 7.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.